A library-based screening method identifies neoantigen-reactive T cells in peripheral blood prior to relapse of ovarian cancer
Open Access
- 21 September 2017
- journal article
- research article
- Published by Taylor & Francis Ltd in OncoImmunology
- Vol. 7 (1), e1371895
- https://doi.org/10.1080/2162402X.2017.1371895
Abstract
Mutated cancer antigens, or neoantigens, represent compelling immunological targets and appear to underlie the success of several forms of immunotherapy. While there are anecdotal reports of neoantigen-specific T cells being present in the peripheral blood and/or tumors of cancer patients, effective adoptive cell therapy (ACT) against neoantigens will require reliable methods to isolate and expand rare, neoantigen-specific T cells from clinically available biospecimens, ideally prior to clinical relapse. Here, we addressed this need using “mini-lines”, large libraries of parallel T cell cultures, each originating from only 2,000 T cells. Using small quantities of peripheral blood from multiple time points in an ovarian cancer patient, we screened over 3.3 × 106 CD8+ T cells by ELISPOT for recognition of peptides corresponding to the full complement of somatic mutations (n = 37) from the patient's tumor. We identified ten T cell lines which collectively recognized peptides encoding five distinct mutations. Six of the ten T cell lines recognized a previously described neoantigen from this patient (HSDL1L25V), whereas the remaining four lines recognized peptides corresponding to four other mutations. Only the HSDL1L25V-specific T cell lines recognized autologous tumor. HSDL1L25V-specific T cells comprised at least three distinct clonotypes and could be identified and expanded from peripheral blood 3–9 months prior to the first tumor recurrence. These T cells became undetectable at later time points, underscoring the dynamic nature of the response. Thus, neoantigen-specific T cells can be expanded from small volumes of blood during tumor remission, making pre-emptive ACT a plausible clinical strategy.Keywords
This publication has 45 references indexed in Scilit:
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung CancerCancer Discovery, 2017
- Genomic correlates of response to CTLA-4 blockade in metastatic melanomaScience, 2015
- Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytesJCI Insight, 2015
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015
- Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencingNature, 2014
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigensNature, 2014
- Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor RegressionsClinical Cancer Research, 2014
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial CancerScience, 2014
- Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cellsNature Medicine, 2013
- A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.The Journal of Experimental Medicine, 1996